FDA launches app for health care professionals to report novel uses of existing medicines for patients with difficult-to-treat infectious diseases
FDA launches CURE ID app for health care professionals
Related Articles
Vivek Subbiah: How to Foster Long-term Trust in the Biomedical Research Process? – OncoDaily
Vivek Subbiah: How to Foster Long-term Trust in the Biomedical Research Process? / Alex C. Cheng, cancer, NEJM Evidence, OncoDaily, Oncology, Paul A. Harris,
Long-Term Obesity and Biological Aging in Young Adults
This cohort study investigates whether long-term obesity in adults aged 28 to 31 years is associated with increased telomere attrition and epigenetic age exceeding chronological…
Inka Health Co-Founders Publish New Study Advancing Real-World Applicability of Lung Cancer Clinical Trial Outcomes
VANCOUVER, BC/ ACCESS Newswire/ June 20, 2025/ Onco-Innovations Limited is pleased to announce that the Co-Founders of its wholly-owned subsidiary, Inka Health Corp., have authored…
Participants as Partners in Decentralized Clinical Trials
Decentralized clinical trials (DCTs), meaning those trials in which activities are conducted outside of hospital or clinic settings, offer many advantages over traditional clinical trials…
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer | NEJM
Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial conducted…
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer | Exelixis, Inc.
The Investor Relations website contains information about Exelixis, Inc.’s business for stockholders, potential investors, and financial analysts.
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes | NEJM
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema)…
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes | NEJM
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema)…
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes | NEJM
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema)…
Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma
PURPOSEAcral lentiginous melanoma is a subtype of cutaneous melanoma arising from palmar, plantar, or subungual skin. These tumors are characterized by aggressive biology, a low…